WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:
Leerink Partners 2025 Global Healthcare Conference
Location: Miami, FL
Presentation: Tuesday, March 11 at 8:00 a.m. ET
1x1 Meetings: Tuesday, March 11
To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the presentation will be available on the Ardelyx website for 30 days following the event.
Jefferies Biotech on the Beach Summit
Location: Miami, FL
1x1 Meetings: Wednesday, March 12
Barclays 27th Annual Global Healthcare Conference
Location: Miami, FL
Fireside Chat: Thursday, March 13 at 10:00 a.m. ET
1x1 Meetings: Thursday, March 13
To access the live webcast of the Barclays Fireside Chat, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.54 |
| Daily Change: | -0.05 -0.89 |
| Daily Volume: | 1,901,757 |
| Market Cap: | US$1.350B |
November 04, 2025 October 28, 2025 October 21, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
